Sutro Biopharma Inc (STRO)

Sutro Biopharma Inc Aktie (STRO) Neueste Nachrichten

Spruce Biosciences, Inc. (SPRB) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research

Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

GlobeNewswire Inc.

Analysts Estimate Sutro Biopharma, Inc. (STRO) to Report a Decline in Earnings: What to Look Out for

Zacks Investment Research

Novavax (NVAX) Reports Q1 Loss, Lags Revenue Estimates

Zacks Investment Research

Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research

Expert Outlook: Sutro Biopharma Through The Eyes Of 10 Analysts

Benzinga

AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock?

Zacks Investment Research

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

GlobeNewswire Inc.

Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday

Benzinga

Navigating 4 Analyst Ratings For Sutro Biopharma

Benzinga

Sutro Biopharma, Inc. (STRO) Q4 Earnings and Revenues Surpass Estimates

Zacks Investment Research

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

GlobeNewswire Inc.

Here's Why Sutro Biopharma (STRO) Is a Great 'Buy the Bottom' Stock Now

Zacks Investment Research

Allogene Therapeutics (ALLO) Reports Q4 Loss, Lags Revenue Estimates

Zacks Investment Research

Sutro Biopharma, Inc. (STRO) Surges 9.5%: Is This an Indication of Further Gains?

Zacks Investment Research

Sutro Biopharma to Participate in Upcoming Investor Conferences

GlobeNewswire Inc.

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024

GlobeNewswire Inc.

Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023

GlobeNewswire Inc.

Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit

GlobeNewswire Inc.

Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer

GlobeNewswire Inc.

Expert Ratings for Sutro Biopharma

Benzinga

Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

GlobeNewswire Inc.

Why Sutro Biopharma (STRO) Might Surprise This Earnings Season

Zacks Investment Research